Andrew Hotchkiss

Andrew Hotchkiss has a diverse work experience spanning over two decades. Andrew is currently the Chief Executive Officer at Draupnir Bio since June 2021. Prior to that, they served as the Chief Executive Officer of Dermira, Inc. from April 2020 to June 2021. Andrew also held the position of Chief Commercial Officer at Immunocore from October 2017 to February 2018, and again from January 2019 to November 2019. Andrew briefly served as the Interim CEO at Immunocore from February 2018 to January 2019.

Before joining Immunocore, Andrew held various roles at Eli Lilly and Company, including Senior Vice President Digital Ventures from February 2017 to September 2017, President Europe, Australia, and Canada from June 2011 to February 2017, Vice President International Business Unit Oncology from November 2009 to June 2011, General Manager of UK and ROI from July 2003 to November 2009, General Manager of Italy from March 1999 to July 2003, and Group Brand Leader US Affiliate from July 1996 to March 1999.

Additionally, Andrew served as a Board Member at the BioIndustry Association from January 2019 to January 2020. Overall, Andrew's work experience demonstrates their expertise in executive leadership and commercial roles within the pharmaceutical and biotech industries.

Andrew Hotchkiss attended Cardiff University / Prifysgol Caerdydd from 1982 to 1985, where they studied Biochemistry.